Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00948064 · ClinicalTrials.gov registry record · Phase 2
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
NCT00948064: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00948064 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 110 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00948064, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if the combination of azacitidine and vorinostat can help to control AML or MDS better than azacitidine alone. The safety of this drug combination will also be studied.
Interventions
- DRUG Azacitidine
- DRUG Vorinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2009-09-08 |
| Est. Completion | 2017-08-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00948064
The ClinicalTrials.gov registry entry for NCT00948064 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Azacitidine is the first listed.
NCT00948064 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00948064 about?
NCT00948064 is a clinical study titled "Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)". The goal of this clinical research study is to learn if the combination of azacitidine and vorinostat can help to control AML or MDS better than azacitidine alone. The safety of this drug combination will also be studied.
What is the current status of trial NCT00948064?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2009-09-08. Estimated completion is 2017-08-03.
What interventions are being tested in trial NCT00948064?
The interventions under investigation include: Azacitidine (DRUG), Vorinostat (DRUG).
Who is sponsoring clinical trial NCT00948064?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.